Related Experiment Video
Updated: Mar 28, 2026

Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Microvesicle phenotypes are associated with transfusion requirements and mortality in subjects with severe injuries
Nena Matijevic1,2, Yao-Wei W Wang3, John B Holcomb1,3
1Department of Surgery, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Background:
Severe injury often results in substantial bleeding and mortality. Injury provokes cellular activation and release of extracellular vesicles. Circulating microvesicles (MVs) are predominantly platelet-derived and highly procoagulant. They support hemostasis and vascular function. The roles of MVs in survival after severe injury are largely unknown. We hypothesized that altered MV phenotypes would be associated with transfusion requirements and poor outcomes.
Methods:
This single-centre study was approved by the Institutional Review Board. The study cohort consisted of patients with major trauma requiring blood product transfusion and 26 healthy controls. Plasma samples for MVs were collected upon admission to the emergency department (n=169) and post-resuscitation (n=42), and analysed by flow cytometry for MV counts and cellular origin: platelet (PMV), erythrocyte (RMV), leukocyte (LMV), endothelial (EMV), tissue factor (TFMV), and annexin V (AVMV). Twenty-four hour mortality is the outcome measurement used to classify survivors versus non-survivors. Data were compared over time and analysed with demographic and clinical data.
Results:
The median age was 34 (IQR 23, 51), 72% were male, Injury Severity Score was 29 (IQR 19, 36), and 24 h mortality was 13%. MV levels and phenotypes differed between patients and controls. Elevated admission EMVs were found both in survivors (409/µL) and non-survivors (393/µL) compared to controls (23/µL, p<0.001) and persisted over time. Admission levels of PMV, AVMV, RMV, and TFMV were significantly lower in patients who died compared to survivors, but were not independently associated with the 24 h mortality rate. Patients with low MV levels at admission received the most blood products within the first 24 h. AVMV and PMV levels either increased over time or stabilized in survivors but decreased in non-survivors, resulting in significantly lower levels at intensive care unit admission in non-survivors (1,048 vs. 1,880 AVMV/µL, p<0.00004 and 1,245 PMP/µL vs. 1,866 PMP/µL, p=0.003).
Conclusion:
Severe injury results in endothelial activation and altered MV phenotypes. Significant differences in specific MV phenotypes or changes over time were associated with blood product requirements and the 24 h mortality rate.
Insights
Microvesicle (MV) phenotypes change after severe injury, impacting transfusion needs and survival. Altered MV levels and types are linked to mortality risk in trauma patients.
Area of Science:
- Trauma and Emergency Medicine
- Vascular Biology
- Coagulation and Hemostasis
Background:
- Severe injury causes significant bleeding and mortality.
- Injury triggers cellular activation and the release of extracellular vesicles, including procoagulant microvesicles (MVs).
- The specific role of MVs in survival following severe trauma remains unclear.
Purpose of the Study:
- To investigate the association between microvesicle (MV) phenotypes and transfusion requirements.
- To determine if MV alterations correlate with outcomes in patients with severe injuries.
- To explore the relationship between MV levels, cellular origin, and 24-hour mortality.
Main Methods:
- A single-center study analyzed plasma samples from 169 major trauma patients and 26 healthy controls.
- Flow cytometry was used to quantify MV counts and cellular origins (platelet, erythrocyte, leukocyte, endothelial, tissue factor, annexin V).
- Samples were collected on admission and post-resuscitation, with 24-hour mortality as the primary outcome measure.
Main Results:
- Patients exhibited distinct MV profiles compared to controls, with elevated endothelial MVs (EMVs) in both survivors and non-survivors.
- Lower admission levels of platelet-derived MVs (PMVs), annexin V MVs (AVMVs), erythrocyte MVs (RMVs), and tissue factor MVs (TF-MVs) were observed in non-survivors.
- Decreased AVMV and PMV levels over time in non-survivors correlated with increased blood product transfusion requirements and higher 24-hour mortality.
Conclusions:
- Severe injury leads to endothelial activation and significant alterations in MV phenotypes.
- Specific MV phenotypes and their dynamic changes over time are associated with the need for blood products and 24-hour mortality in trauma patients.
Related Concept Videos
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Blood Transfusion
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

